Trevi Therapeutics announced positive topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with refractory chronic cough (RCC). Haduvio met the primary endpoint with a statistically significant reduction in 24-hour cough frequency (p<0.0001).
The trial demonstrated a 67% reduction from baseline and a 57% placebo-adjusted reduction in objective 24-hour cough frequency. Similar efficacy was observed in both severe (66% reduction) and moderate (68% reduction) cough subgroups.
Haduvio is now the first and only therapy in clinical development to show a statistically significant reduction in chronic cough across both RCC and IPF patients. Patient-reported outcomes also showed statistically significant improvements as early as Day 7, and the safety profile was consistent with previous trials, with no treatment-emergent serious adverse events.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.